• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    (OP: PMBHF )

    N/A UNCHANGED
    Last Price Updated: 9:46 AM EST, Jan 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about PMBHF

    Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
    Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.  
    Via Benzinga
    Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA's Stance, The Therapist's Role & More
    Welcome to Benzinga's weekly psychedelics news roundup. We have pulled together several must-read news items from the last week of December 2023 and the first of January 2024.  
    Via Benzinga
    Canada To Australia: New MDMA & Psilocybin Shipment On Its Way For Legal Therapeutic Market
    The first of several of PharmAla Biotech’s (OTC: PMBHF) shipments of psychedelic molecules -both API and finished drug product capsules- to its Australian JV Cortexa for use under the Authorized... 
    Via Benzinga
    Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
    First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
    Via Benzinga
    Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
    A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
    Via Benzinga
    PharmAla Files IP Protection For Novel MDXX Molecule: Viability As Autism Spectrum Treatment
    Canadian biotech company PharmAla Biotech Holdings (OTC: PMBHF) has filed a patent covering composition of matter of Novel Chemical Entity (NCE) PharmAla-1.  
    Via Benzinga
    Cybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical Trials
    Cybin One Steps Away From Complete Dosing 
    Via Benzinga
    Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
    First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic... 
    Via Benzinga
    PharmAla's Australian JV Cortexa Orders First Commercial MDMA & Psilocybin Shipment
    As Australia’s psychedelic program launches, PharmAla Biotech Holdings Inc.’s (OTC: PMBHF) new 
    Via Benzinga
    MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University
    Numinus Wellness (OTCMKTS: NUMIF) with support from the Multidisciplinary Association for Psychedelic Studies (MAPS) will utilize Optimi Health’s (OTCMKTS: OPTHF) Good Manufacturing Practice... 
    Via Benzinga
    Canadian Financing: PharmAla Biotech Offers Non-Brokered Private Placement Up To $3.76M
    MDXX-class molecules biotech company PharmAla Biotech Holdings Inc. (OTCMKTS: PMBHF) has announced a non-brokered private placement of a minimum of 3.3 million units and a maximum of 16.6 million of... 
    Via Benzinga
    Promising Milestone: FDA Approves California-Based Trial Assessing MDMA For Schizophrenia
    The FDA has approved a clinical trial that will assess PharmAla Biotech Holdings' (OTC: PMBHF) proprietary LaNeo Investigational Medical Product (IMP) 40mg MDMA capsules for the treatment of... 
    Via Benzinga
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.